SagarLonialMD

Hematology • Atlanta, GA

Hematologic Oncology

Professor, Hematology and Medical Oncology, Emory University School of Medicine

Join to view full profile

Dr. Lonial is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lonial's full profile

Already have an account?

Office
1365 Clifton Rd Ne
Atlanta, GA 30322
Phone+1 404-778-1900

Education & Training

Emory University School of MedicineFellowship, Hematology and Medical Oncology, 1997 - 2000
Baylor College of MedicineResidency, Internal Medicine, 1993 - 1997
University of Louisville School of MedicineClass of 1993

Certifications & Licensure

GA State Medical License 1997 - 2025
TX State Medical License 1995 - 1999

Clinical Trials

Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma Start of enrollment: 2008 Dec 01
Withdrawn
Phase 1
Study of MLN4924, a Novel Inhibitor of Nedd8 Activating Enzyme, in Adult Patients With Lymphoma or Multiple Myeloma Start of enrollment: 2008 Jun 01
Completed
Phase 1
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Start of enrollment: 2011 Jul 01
Completed
Phase 1, Phase 2
Relating Clinical Outcomes in Multiple Myeloma to Personal Assessment of Genetic Profile Start of enrollment: 2011 Jul 01
Completed
ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma Start of enrollment: 2014 Mar 01
Active, not recruiting
Phase 1, Phase 2
Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment Start of enrollment: 2020 Feb 10
Completed
Phase 1
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) Start of enrollment: 2021 Apr 20
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
Trial of LAVA-051 in Patients With Relapsed/Refractory CLL, MM, or AML Start of enrollment: 2021 Jul 12
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

600 citations
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Antonio Palumbo, S V Rajkumar, Meletios A. Dimopoulos, Paul G. Richardson, J F San Miguel
Leukemia. 2008-02-01
41 citations
A Phase 1 and 2 study of Filanesib alone and in combination with low‐dose dexamethasone in relapsed/refractory multiple myeloma
Jatin J. Shah, Jonathan L. Kaufman, Jeffrey A. Zonder, Adam D. Cohen, William I. Bensinger
Cancer. 2017-12-01
159 citations
Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma.
Tineke Casneuf, Xu Steven Xu, Homer Adams, Amy Axel, Christopher Chiu
Blood Advances. 2017-10-24

Journal Articles

Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C Munshi, Larry D Anderson, Deepu Madduri, Sagar Lonial, Noopur Raje, Fabio Petrocca, Kristen Hege, The New England Journal of Medicine
Article MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK Activation
Guojing Zhang, Fadlo R Khuri, Taofeek K Owonikoko, Dan Li, Conor E Steuer, Nabil F Saba, Dong M Shin, Sagar Lonial, ScienceDirect
A Phase I/II Dose-Escalation Study Investigating All-Oral Ixazomib-Melphalan-Prednisone Induction Followed by Single-Agent Ixazomib Maintenance in Transplant-Ineligibl...
Michael D Craig, Sagar Lonial, Haematologica
Identification of Novel Mutational Drivers Reveals Oncogene Dependencies in Multiple Myeloma
Nikhil Munshi, Kenneth C Anderson, A Keith Stewart, Sagar Lonial, Blood
Join now to see all

Abstracts/Posters

Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Final Analysis of a Phase 1b Study of Daratumumab in Combination with Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma (RRMM)Clinically Releva...
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Multiple Myeloma Epigenetic Programming Prognostic of Outcome Converges with Loci Reprogrammed in Relapsed/Refractory Disease
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Unsupervised Clustering of DNA Copy Number Profiles Identifies a High-Risk Subtype of Hyperdiploid Multiple Myeloma: An Mmrf Commpass Analysis
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans
Sagar Lonial, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Molecular Characterization of Bone Marrow and Peripheral Blood Compartments from Patients with Plasma Cell Leukemia in the Mmrf Commpass Study
Sagar Lonial, 61st Annual American Society of Hematology Meeting, 61st Annual American Society of Hematology Meeting - Orlando, FL, 12/7/2019
Join now to see all

Lectures

Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Amyloidosis and Waldenstr_m Macroglobulinemia (Part 2 of a 2-Part Series)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Translational and Clinical Evidence of a Differentiated Profile for the Novel CELMoD, Iberdomide (CC-220)
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.
2019 ASCO Annual Meeting - 6/1/2019
First clinical (phase 1b/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple ...
2019 ASCO Annual Meeting - 6/1/2019
Split First Dose Administration of Daratumumab for the Treatment of Patients with Multiple Myeloma (MM): Clinical Pharmacology and Population Pharmacokinetic (PK) Anal...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Phase II Trial of Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized with NFKB2 Rearrangement. (Proteasome Inhibitor NFKB2 Rearrang...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Outcomes of Myeloma Patients with Deletion 1p Receiving Lenalidomide, Bortezomib, and Dexamethasone (RVD) Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Analysis of Sequential Patient Samples from the Mmrf Commpass Study Identifies a High Risk Progression Phenotype
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
An Integrated Genomics Analysis Identifies Recurrent Gain- and Loss-of-Function Events and in Distinct Subtypes of Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Evaluation of All Cause of Death after High Dose Chemotherapy and Autologous Stem Cell Transplant in Hodgkin Lymphoma and Non-Hodgkin Lymphoma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Development and Validation of a High Risk Multiple Myeloma Gene Expression Index from RNA Sequencing: An Mmrf Commpass Analysis
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Addressing Current Questions and Controversies in the Management of Multiple Myeloma, Waldenstrom Macroglobulinemia, and Amyloidosis (Part 2 of a 2-Part Series)
60th American Society of Hematology Annual Meeting - 11/30/2018
Extended 5-y follow-up (FU) of phase 3 ELOQUENT-2 study of elotuzumab + lenalidomide/dexamethasone (ELd) vs Ld in relapsed/refractory multiple myeloma (RRMM).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Ninth Annual Hematology Conference: An Update on Selected ASH Topics
The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee - 1/19/2013
Join now to see all

Press Mentions

Landmark Study Reveals New Insights into Multiple Myeloma ProgressionAugust 19th, 2024
Georgia's First Immediate Care Center Specifically for Patients with Cancer Opens at WinshipApril 15th, 2022
Gift Honoring David Lawson, MD, Endows Cancer Research Professorship at WinshipFebruary 4th, 2022
Join now to see all